Dr. Reddy’s Laboratories Limited (NYSE:RDY) Shares Bought by Orion Portfolio Solutions LLC

Orion Portfolio Solutions LLC increased its position in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 43.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,524 shares of the company’s stock after acquiring an additional 6,192 shares during the period. Orion Portfolio Solutions LLC’s holdings in Dr. Reddy’s Laboratories were worth $1,631,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of RDY. Frank Rimerman Advisors LLC acquired a new stake in Dr. Reddy’s Laboratories in the second quarter valued at $2,633,000. Caprock Group LLC acquired a new stake in Dr. Reddy’s Laboratories in the 2nd quarter valued at about $997,000. Natixis Advisors LLC purchased a new position in Dr. Reddy’s Laboratories during the 2nd quarter valued at about $777,000. Dimensional Fund Advisors LP raised its position in Dr. Reddy’s Laboratories by 12.8% during the second quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company’s stock worth $76,455,000 after acquiring an additional 114,294 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in Dr. Reddy’s Laboratories during the second quarter worth about $557,000. 3.85% of the stock is owned by hedge funds and other institutional investors.

Dr. Reddy’s Laboratories Trading Up 0.4 %

Shares of RDY stock opened at $14.46 on Friday. The company has a market capitalization of $12.07 billion, a price-to-earnings ratio of 23.10 and a beta of 0.53. The company has a current ratio of 1.92, a quick ratio of 1.36 and a debt-to-equity ratio of 0.02. The firm has a 50-day moving average price of $14.88 and a 200 day moving average price of $15.36. Dr. Reddy’s Laboratories Limited has a twelve month low of $13.26 and a twelve month high of $16.89.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. StockNews.com cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th. Barclays lowered their target price on Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.